GlassScriptPhysician profile
Mikel A Cross
NPI 1407127202
$5,765.72
in general payments reported to CMS, 2019-2025
30 companies · $1,675 in 2025
The $1,675 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $779 · 2023: $2,254 · 2024: $1,057 · 2025: $1,675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,855 · Education: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,855.31 |
| Education | $131.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,886.48 | 2022-2025 | |
| Janssen Biotech, INC. | $651.66 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $584.84 | 2022-2025 | Entyvio, Gattex, Eohilia |
| Ardelyx, INC. | $255.40 | 2022-2025 | Ibsrela |
| Lilly USA, LLC | $233.35 | 2023-2025 | Omvoh |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $211.85 | 2022-2024 | Trulance |
| Regeneron Healthcare Solutions, INC. | $201.02 | 2022-2025 | Dupixent |
| Nestle Healthcare Nutrition INC. | $167.24 | 2022-2023 | |
| Genzyme Corporation | $163.06 | 2022-2025 | |
| Qol Medical, LLC | $150.99 | 2023-2025 | Sucraid, Sucraid |
| Merck Sharp & Dohme LLC | $121.39 | 2022-2024 | Dificid |
| Madrigal Pharmaceuticals | $116.12 | 2025 | Rezdiffra |
| Gilead Sciences, INC. | $109.16 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $97.76 | 2023 | Zeposia |
| Celltrion USA INC. | $93.90 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $92.70 | 2023-2024 | |
| Celgene Corporation | $86.50 | 2023-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $84.33 | 2024-2025 | Zenpep |
| Enterra Medical, INC. | $80.00 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $56.83 | 2024-2025 | Iqirvo |
| Pharmacosmos Therapeutics INC. | $55.34 | 2023-2025 | Monoferric |
| Ironwood Pharmaceuticals, INC | $51.21 | 2023-2024 | Linzess |
| Amgen INC. | $44.06 | 2022-2023 | Amjevita, Avsola |
| Novo Nordisk INC | $38.19 | 2025 | Wegovy |
| Mallinckrodt Hospital Products INC. | $29.81 | 2022 | |
| Phathom Pharmaceuticals, INC. | $26.39 | 2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $21.48 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $20.00 | 2023 | Andexxa |
| Daiichi Sankyo INC. | $18.92 | 2022 | |
| Fresenius Kabi USA, LLC | $15.74 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mikel Cross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.